Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Selenium Supplementation Effect on Glycemic Control: A Grade-Assessed Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials Publisher Pubmed



Vajdi M1 ; Hassanizadeh S1 ; Gholami Z1 ; Bagherniya M2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Nutrition and Food Security Research Center and Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Pharmacological Research Published:2023


Abstract

Results: from different studies on the effects of selenium supplementation on glycemic control are still debated. To fill this knowledge gap, we investigated the overall effects of selenium supplementation on some glycemic parameters such as fasting blood sugar (FBS), hemoglobinA1c (HbA1c), fasting insulin, quantitative insulin sensitivity check index (QUICKI), and homeostatic model assessment of insulin resistance (HOMA-IR). A comprehensive literature search was conducted from inception to April 2023 on Scopus, Web of Science, PubMed, Google Scholar, and Cochrane databases. All randomized controlled trials (RCTs) which reported an effect of selenium supplementation on glycemic parameters were included. A random-effects model was used to estimate the weighted mean difference (WMD) and 95% CI for each outcome. Between-studies heterogeneity was assessed by the I2 and Cochran's Q test. 20 trials were included in the meta-analysis. Pooled analysis showed that selenium intake significantly reduced fasting insulin (WMD: −3.02 µIu/mL, 95% CI; −5.13, −0.90, P = 0.005) and increased QUICKI levels (WMD: 0.01, 95% CI: 0.01, 0.02, P = 0.005). However, selenium supplementation did not change FBS (WMD: −1.32 mg/dL, 95% CI; −4.02, 1.37, P = 0.332), HbA1c (WMD = 0.05%, 95% CI: −0.19, 0.28, p = 0.701), and HOMA-IR (WMD: −0.82, 95% CI; −2.14, 0.50, P = 0.223). Moreover, we found that there is a non-linear association between selenium supplementation dosage and FBS (P-nonlinearity = 0.008). In conclusion, our study findings indicate some benefits of selenium on fasting insulin, and QUICKI compared with placebo, but elicits no effect on HbA1c, HOMA-IR, and FBS. Further well-designed RCTs with larger samples are necessary to ascertain the effects of selenium supplementation on glycemic control. © 2023 The Authors
Experts (# of related papers)
Other Related Docs